Lockdown of the elderly is misguided policy

By Franklin G. Miller. The Covid-19 pandemic poses policy challenges that may call for controversial measures.  Savulescu and Cameron have recently argued in favor of “lockdown “of the elderly as a reasonable alternative to the population-wide lockdowns that have been implemented during the pandemic in various jurisdictions around the world. They claim correctly that such […]

Read More…

The ethics of State-sponsored and clinical promotion of long-acting reversible contraception

Originally published in the BMJ Sexual and Reproductive Health Blog. By Jeffrey Wale and Sam Rowlands. Global responses to the Covid-19 pandemic offer a good opportunity to re-examine the role of State actors (policymakers, regulatory bodies, clinical commissioning groups, service providers) and healthcare professionals in the promotion of health-related behaviours.  Just how far should healthcare […]

Read More…

How should the risks of infecting research participants with SARS-CoV-2 be assessed?

By Susan Bull, Euzebiusz Jamrozik, Ariella Binik, Michael Parker Vaccine development processes typically take ten to twenty years. The exceptional pace of COVID-19 vaccine research has resulted in early human trials being commenced with vaccine candidates. Calls have been made to conduct controlled human infection studies (CHIs), also known as challenge studies, with SARS-CoV-2 to […]

Read More…

Ethical oversight during COVID-19: rewriting the norms of research ethics review?

By Anna Chiumento and Lucy Frith One consequence of physical distancing in response to the COVID-19 pandemic has been the rapid suspension or adaptation of ongoing research activity.  This presents an opportunity for the research ethics community and researchers to promote ethical oversight that integrates the situated and informed judgement of researchers, rebalancing away from […]

Read More…

Is Research Ethics Committee review of most clinical trials fundamentally broken?

By Mark Yarborough Imagine that you suffered from a fatal neurodegenerative disorder like Alzheimers or ALS, or that you had a serious chronic condition like hypertension or heart disease. Imagine further that you were asked to participate in a clinical trial related to your disease. Finally, imagine that the person recruiting you into the trial […]

Read More…

Pandemic priority decisions and triage, from good to ugly

By Hans Flaatten, Michael Beil, and Susannah Leaver. The present COVID-19 pandemic has fuelled discussions regarding the prospects and limitations of treatment in critically ill patients. This commentary describes a framework for understanding pandemic triage ranging from “business as usual” (“good”) to the extreme depletion of all resources (“ugly”). This is illustrated with different stages […]

Read More…

COVID, Systemic Racism Protests, Anti-Lockdown Protests: Making Sense Of It All

By Austin Lam. A recent article highlighted an uncomfortable yet unassailable issue: “the way the public health narrative around coronavirus has reversed itself overnight seems an awful lot like … politicizing science.” Alternatively, another article frames this political element as itself the impetus to justify protests against systemic racism in the context of racism as […]

Read More…